

Rev04
Update: Oct,19,2022

DATASHEET

Anti-Nivolumab Antibody (6G5), mAb, Mouse

Cat. No.: A01965

Overview

Specificity	The product is specific for Nivolumab. The antibody is recommended as a detection antibody in a pharmacokinetic (PK) bridging assay with capture antibody GenScript, A01847-40, Anti- Nivolumab Antibody (8G6G3D8), mAb, Mouse.
Host Species	Mouse
Immunogen	Nivolumab
Conjugate	Unconjugated

Applications

Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.


Application	Recommended Usage
ELISA	0.01-0.1 µg/ml

Properties

Form	Lyophilized
Storage Buffer	lyophilized with PBS, pH 7.4, containing 0.02% sodium azide.
Reconstitution	Reconstitute the lyophilized powder with deionized water (or equivalent) to an final concentration of 0.5 mg/mL.
Storage Instructions	The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.
Purification	Protein A affinity column
Isotype	Mouse IgG1

Clonality	Monoclonal
Clone ID	6G5
Note	GenScript can customize this product per customer's request including product size, buffer components, etc.

Examples



ELISA binding of Anti-Nivolumab Antibody (6G5), mAb, Mouse (GenScript, A01965-40) with Nivolumab. While the antibody does not recognize the human IgG Fc fragment (data not shown).

Coating antigen: Nivolumab, 1 µg/ml.

Anti-Nivolumab antibody (GenScript, A01965-40) dilution start from 1,000 ng/ml.

EC₅₀= 3.01ng/ml.

Background

Target Background : Nivolumab (Opdivo) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Nivolumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells. GenScript Anti-Nivolumab Antibody (6G5), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Nivolumab.

Synonyms : Mouse monoclonal to Opdivo

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.